Fused Deposition Modeling as a Possible Approach for the Preparation of Orodispersible Tablets.
3D printing
disintegration time
domperidone
fused deposition modeling
hot-melt extrusion
orodispersible tablets
paracetamol
solid dosage forms
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
05 Jan 2022
05 Jan 2022
Historique:
received:
29
11
2021
revised:
30
12
2021
accepted:
02
01
2022
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
Additive manufacturing technologies are considered as a potential way to support individualized pharmacotherapy due to the possibility of the production of small batches of customized tablets characterized by complex structures. We designed five different shapes and analyzed the effect of the surface/mass ratio, the influence of excipients, and storage conditions on the disintegration time of tablets printed using the fused deposition modeling method. As model pharmaceutical active ingredients (APIs), we used paracetamol and domperidone, characterized by different thermal properties, classified into the various Biopharmaceutical Classification System groups. We found that the high surface/mass ratio of the designed tablet shapes together with the addition of mannitol and controlled humidity storage conditions turned out to be crucial for fast tablet's disintegration. As a result, mean disintegration time was reduced from 5 min 46 s to 2 min 22 s, and from 11 min 43 s to 2 min 25 s for paracetamol- and domperidone-loaded tablets, respectively, fulfilling the European Pharmacopeia requirement for orodispersible tablets (ODTs). The tablet's immediate release characteristics were confirmed during the dissolution study: over 80% of APIs were released from printlets within 15 min. Thus, this study proved the possibility of using fused deposition modeling for the preparation of ODTs.
Identifiants
pubmed: 35056125
pii: ph15010069
doi: 10.3390/ph15010069
pmc: PMC8781976
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Science Center
ID : 2018/31/B/ST8/01327
Organisme : Funding Agency of Charles University
ID : SVV 260 547
Références
Int J Pharm. 2018 Jul 10;545(1-2):144-152
pubmed: 29705104
Eur J Pharm Biopharm. 2020 Apr;149:58-76
pubmed: 31982577
J Pharm Biomed Anal. 2018 Feb 20;150:333-340
pubmed: 29287259
Int J Pharm. 2020 Aug 30;586:119591
pubmed: 32640268
Molecules. 2021 May 22;26(11):
pubmed: 34067434
Indian J Pharm Sci. 2010 Mar;72(2):245-9
pubmed: 20838533
Drug Dev Ind Pharm. 2021 Feb 1;:1-10
pubmed: 33493008
Eur J Pharm Sci. 2020 Dec 1;155:105558
pubmed: 32946957
Int J Pharm. 2021 Apr 15;599:120402
pubmed: 33640426
Int J Pharm. 2021 Dec 15;610:121194
pubmed: 34728321
J Pharm Sci. 2017 Jul;106(7):1697-1705
pubmed: 28347731
Pharm Dev Technol. 2016;21(3):354-66
pubmed: 25560782
Pharm Res. 2018 Jul 11;35(9):176
pubmed: 29998405
Pharmaceutics. 2020 Mar 05;12(3):
pubmed: 32150899
J Control Release. 2018 Jan 10;269:355-363
pubmed: 29146240
Int J Pharm Investig. 2014 Oct;4(4):174-82
pubmed: 25426438
Materials (Basel). 2020 Nov 04;13(21):
pubmed: 33158192
Eur J Pharm Sci. 2015 Jul 30;75:2-9
pubmed: 25736528
Pharmacy (Basel). 2020 Oct 10;8(4):
pubmed: 33050437
J Pharm Sci. 2020 Apr;109(4):1558-1572
pubmed: 32004538
Acta Pharm. 2011 Jun;61(2):117-39
pubmed: 21684842
Pharmaceutics. 2021 Mar 09;13(3):
pubmed: 33803163
Polymers (Basel). 2020 Aug 20;12(9):
pubmed: 32825229
AAPS PharmSciTech. 2015 Apr;16(2):234-41
pubmed: 25739913
Int J Pharm. 2015 Oct 30;494(2):657-663
pubmed: 25934428
Clin Interv Aging. 2016 Oct 07;11:1403-1428
pubmed: 27785002
Eur J Pharm Biopharm. 2015 Jan;89:157-62
pubmed: 25497178
Eur J Pharm Sci. 2020 Feb 15;143:105169
pubmed: 31785383
Adv Ther. 2010 Nov;27(11):785-95
pubmed: 20878372
Int J Pharm. 2020 Dec 15;591:119987
pubmed: 33069894
Eur J Pharm Sci. 2018 Jun 15;118:191-199
pubmed: 29559404
Eur J Pharm Biopharm. 2018 Oct;131:44-47
pubmed: 30048746
Polymers (Basel). 2020 Dec 20;12(12):
pubmed: 33419348
Int J Pharm. 2017 Aug 7;528(1-2):268-279
pubmed: 28583328